胆碱C-11(CHOLINE C-11) - 在研适应症：前列腺癌_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

11C-choline、11C-choline chloride

靶点-

作用方式-

作用机制-

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

前列腺癌

非在研适应症-

原研机构

MAYO CLINIC PET RADIOCHEMISTRY FACILITY

在研机构

MAYO CLINIC PET RADIOCHEMISTRY FACILITY

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2012-09-12),

前列腺癌

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C5H14ClNO

InChIKeySGMZJAMFUVOLNK-ULWFUOSBSA-M

CAS号87591-54-6

关联

17

项与胆碱C-11 相关的临床试验

NCT05087134

/ Unknown status早期临床1期IIT

Characterizing Lymphangioleiomyomatosis (LAM) With 11C-Choline PET/CT

It was reported that TSC2-deficient cells enhance phosphatidylcholine synthesis via the Kennedy pathway. 11C-Choline can reflect the metabolic process of choline in vivo by intravenous injection. The purpose of this study is the ability of 11C-Choline PET/CT to evaluate the baseline condition of LAM patients and the efficacy of rapamycin after treatment.

开始日期2021-11-01

申办/合作机构

北京协和医院

NCT04693169

/ Active, not recruitingN/AIIT

[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients

To investigate the radioactive uptake of [Al 18 F]PSMA137 in PCa patients, and evaluate the ability of [Al 18 F]PSMA137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).To provide an approach for screening patients high expression of PSMA, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.

开始日期2021-01-15

申办/合作机构

北京市肿瘤防治研究所

NCT04560725

/ Active, not recruitingN/AIIT

PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer

To study the radioactive uptake of [68Ga]P137 in the lesion sites of PCa patients and evaluate the ability of [68Ga]P137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).

开始日期2020-10-22

申办/合作机构-

100 项与胆碱C-11 相关的临床结果

登录后查看更多信息

100 项与胆碱C-11 相关的转化医学

登录后查看更多信息

100 项与胆碱C-11 相关的专利（医药）

登录后查看更多信息

9

项与胆碱C-11 相关的文献（医药）

2020-08-01·Journal of Urology1区 · 医学

Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections

1区 · 医学

Article

作者: Gill, Inderbir S. ; Joniau, Steven ; Fossati, Nicola ; Buchner, Alexander ; Mottrie, Alexander ; Boeri, Luca ; Battaglia, Antonino ; Hiester, Andreas ; Tilki, Derya ; Montorsi, Francesco ; Juenemann, Klaus-Peter ; Karnes, R. Jeffrey ; Suardi, Nazareno ; Van Poppel, Hendrik ; Nini, Alessandro ; Heidenreich, Axel ; Pfister, David ; Graefen, Markus ; Stief, Christian ; Osmonov, Daniar ; Kretschmer, Alexander ; Shariat, Shahrokh ; Scarcella, Simone ; Galosi, Andrea Benedetto ; Briganti, Alberto ; Albers, Peter ; Robesti, Daniele ; Gandaglia, Giorgio

PURPOSEWe compared the use of ¹¹C-choline and ⁶⁸Ga-prostate specific membrane antigen in men undergoing salvage lymph node dissection for nodal recurrent prostate cancer.MATERIALS AND METHODSThe study included 641 patients who experienced prostate specific antigen rise and nodal recurrence after radical prostatectomy and underwent salvage lymph node dissection. Lymph node recurrence was documented by positron emission tomography/computerized tomography using ¹¹C-choline (407, 63%) or ⁶⁸Ga-PSMA ligand (234, 37%). The outcome was underestimation of tumor burden (difference between number of positive nodes on final pathology and number of positive spots at positron emission tomography/computerized tomography). Multivariable analysis tested the association between positron emission tomography/computerized tomography tracer (¹¹C-choline vs ⁶⁸Ga-PSMA) and tumor burden underestimation.RESULTSOverall the extent of tumor burden underestimation was significantly higher in the ¹¹C-choline group compared to the ⁶⁸Ga-PSMA group (p <0.0001), which was confirmed on multivariable analysis (p=0.028). Repeating these analyses according to prostate specific antigen, tumor burden underestimation was lower with ⁶⁸Ga-PSMA only when prostate specific antigen was 1.5 ng/ml or less. Conversely, the underestimation of the 2 tracers became similar when prostate specific antigen was greater than 1.5 ng/ml. Furthermore, we evaluated the risk of underestimation by number of positive spots on positron emission tomography/computerized tomography. The higher the number of positive spots the higher the underestimation of tumor burden regardless of the tracer used (p=0.2).CONCLUSIONSPositron emission tomography/computerized tomography significantly underestimates the burden of prostate cancer recurrence, regardless of the tracer used. ⁶⁸Ga-PSMA was associated with a lower rate of underestimation in patients with a prostate specific antigen below 1.5 ng/ml and a limited nodal tumor load. In all other men there was no benefit from ⁶⁸Ga-PSMA over ¹¹C-choline in assessing the extent of nodal recurrence.

2019-12-01·EJNMMI Research

Optimization of parathyroid 11C-choline PET protocol for localization of parathyroid adenomas in patients with primary hyperparathyroidism

Article

作者: Telenga, Eef D ; Noordzij, Walter ; Hubalewska-Dydejczyk, Alicja ; El Moumni, Mostafa ; Boellaard, Ronald ; Brouwers, Adrienne H ; Opalińska, Marta ; Luurtsema, Gert ; Kruijff, Schelto ; Noltes, Milou E ; Vállez García, David ; Trofimiuk-Müldner, Malgorzata ; Dierckx, Rudi A J O

PURPOSETo evaluate the optimal tracer uptake time, the minimal amount of radioactivity and the inter-observer agreement for ¹¹C-choline positron emission tomography/computed tomography (PET/CT) in patients with primary hyperparathyroidism (pHPT).METHODSTwenty-one patients with biochemically proven pHPT were retrospectively studied after injection of 6.3 ± 1.2 MBq/kg ¹¹C-choline. PET data of the first nine patients, scanned for up to 60 min, were reconstructed in 10-min frames from 10- to 60-min postinjection (p.i.), mimicking varying ¹¹C-choline uptake times. Parathyroid adenoma to background contrast ratios were calculated and compared, using standardized uptake values (SUVs). Data was reconstructed with varying scan durations (1, 2.5, 5, and 10 min) at 20-30-min p.i. (established optimal uptake time), mimicking less administered radioactivity. To establish the minimal required radioactivity, the SUVs in the shorter scan durations (1, 2.5, and 5 min) were compared to the 10-min scan duration to determine whether increased variability and/or statistical differences were observed. Four observers analyzed the ¹¹C-choline PET/CT in four randomized rounds for all patients.RESULTSSUVpeak of the adenoma decreased from 30 to 40 p.i. onwards. All adenoma/background contrast ratios did not differ from 20- to 30-min p.i. onwards. The SUVs of adenoma in the scan duration of 1, 2.5, and 5 min all differed significantly from the same SUV in the 10-min scan duration (all p = 0.012). However, the difference in absolute SUV adenoma values was well below 10% and therefore not considered clinically significant. The inter-observer analysis showed that the Fleiss' kappa of the 1-min scan were classified as "moderate," while these values were classified as "good" in the 2.5-, 5-, and 10-min scan duration. Observers scored lower certainty scores in the 1- and 2.5-min scans compared to the 5- and 10-min scan durations.CONCLUSIONThe optimal time to start PET/CT scanning in patients with pHPT is 20 min after mean injection of 6.3 MBq/kg ¹¹C-choline, with a recommended scan duration of at least 5 min. Alternatively, the radioactivity dose can be lowered by 50% while keeping a 10-min scan duration without losing the accuracy of ¹¹C-choline PET/CT interpretation.

2013-09-01·Clinical Nuclear Medicine3区 · 医学

The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level <0.5 ng/mL

3区 · 医学

Article

作者: Ceci, Francesco ; Costa, Stefano ; Fanti, Stefano ; Fuccio, Chiara ; Brunocilla, Eugenio ; Castellucci, Paolo ; Nanni, Cristina ; Mamede, Marcelo ; Schiavina, Riccardo ; Colletti, Patrick M ; Fantini, Lorenzo ; Ferretti, Alice ; Rubello, Domenico

PURPOSEThis study aims to evaluate the role of (11)C-choline PET/CT in patients with biochemical relapse after radical prostatectomy (RP) showing prostate-specific antigen (PSA) values lower than 0.5 ng/mL.METHODSWe performed (11)C-choline PET/CT in 71 consecutive patients previously treated with RP showing PSA values lower than 0.5 ng/mL. (11)C-Choline PET/CT was performed following standard procedure. (11)C-Choline PET/CT-positive findings were validated by transrectal ultrasonography + biopsy, repeated (11)C-choline PET/CT, other conventional imaging modality, and histology.RESULTS(11)C-Choline PET/CT was true positive in 15/71 (21.1%). (11)C-Choline uptake was observed in pelvic lymph nodes (7/71; 9.9%), in the prostatic bed (7/71; 9.9%), and in bone (1/71; 1.4%). Mean PSA, PSA doubling time (PSAdt), and PSA velocity (PSAvel) values ± SD in (11)C-choline PET/CT-positive patients was 0.37 ± 0.1 ng/mL, 3.4 ± 2.1 months, and 0.05 ± 0.1 ng/mL/yr, respectively. (11)C-Choline PET/CT was false negative in 2 patients and false positive in 1 patient. Among all variables, only PSAdt and the ongoing hormonal treatment were statistically significant in the prediction of a positive (11)C-choline PET/CT at multivariate analysis.CONCLUSIONS(11)C-Choline PET/CT could be used early after biochemical failure even if PSA values are very low, preferentially in hormonal resistant patients showing fast PSA kinetics. An early detection of the site of relapse could lead to a personalized and tailored treatment.

100 项与胆碱C-11 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10498	胆碱C-11	V09	DB09277

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
前列腺癌	美国	MAYO CLINIC PET RADIOCHEMISTRY FACILITY	2012-09-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2024	N/A	尿路上皮癌	-	11C-Choline (2-min <sup>11</sup>C-CHO TB PET/CT scan)	廠鹹齋網獵構憲醖鬱夢(窪衊製餘積憲齋鑰憲遞) = There were no statistically significant differences in the distant organ metastasis by dual-phase imaging 選艱範築鑰鹹鹽艱衊蓋 (築窪築獵築糧選蓋獵齋 ) 更多	-	2024-06-09
				11C-Choline (1-h <sup>11</sup>C-CHO TB PET/CT scan)
EANM2021	N/A	前列腺癌辅助 serum PSA	103	[11C]Choline (Radical Prostatectomy (RP))	繭衊選顧鹽構壓衊衊製(範衊製範淵淵憲鬱遞構) = 壓糧餘蓋齋獵齋廠餘鹹齋鏇鏇顧範築衊鹹獵艱 (網簾遞築糧繭餘製顧憲 ) 更多	积极	2021-09-24
				Other forms of treatment (radiotherapy, chemotherapy, hormonotherapy)	(構壓鑰鏇淵膚範鹹獵鹽) = 齋衊繭築築夢鏇襯繭憲襯糧網齋醖憲窪鏇衊鬱 (選襯艱顧簾鹽醖憲鑰鑰 )
EANM2020	N/A	甲状旁腺疾病	60	11C-Choline (Dual Isotope SPECT/CT)	(艱壓糧餘願壓選選遞網) = 製願築鹽願膚鬱淵齋淵蓋鹽淵鑰鑰廠艱餘鬱顧 (廠顧鬱觸獵積遞蓋顧遞, 90% ~ 100%)	-	2020-09-18
NCT02260817 (CTgov)	临床3期	复发性前列腺癌 \| 转移性前列腺癌	109	11C-choline (11C-choline for Staging of Recurrent Prostate Cancer)	齋遞艱鏇遞築襯壓構淵(簾願艱餘鏇鏇鏇願範構) = 鹹醖廠襯鬱窪衊襯製醖膚蓋構壓醖餘襯積網齋 (醖廠觸簾網鬱獵襯獵衊, 齋壓繭餘願顧壓網鬱齋 ~ 範淵膚艱築鏇蓋鹽觸衊) 更多	-	2019-12-17
				11C-choline (11C-choline Comparison Study of CT and MR Modalities)	齋遞艱鏇遞築襯壓構淵(簾願艱餘鏇鏇鏇願範構) = 淵顧鏇窪廠膚襯鏇製願膚蓋構壓醖餘襯積網齋 (醖廠觸簾網鬱獵襯獵衊, 窪遞鹹憲壓壓鑰顧遞淵 ~ 鏇簾衊鑰衊選鹹願遞窪) 更多
SNMMI2019	N/A	-	-	11C-CHOLINE18F-FDGLINE (18F-FDG PET/CT)	鹹蓋鹽觸齋蓋淵醖選齋(製鑰獵範積鹹願襯艱簾) = 鹽糧簾夢構選簾艱遞餘選憲窪範構艱網鏇構淵 (選壓鬱淵鏇鏇蓋夢鬱遞 ) 更多	-	2019-05-21
EANM2018	N/A	前列腺癌	-	11C-Choline (PET/MR C11-Choline WB scan)	鏇遞淵蓋築餘夢衊壓艱(獵鬱衊範醖選獵餘淵網) = 糧醖構鹽齋憲觸範鏇襯願艱艱鹽廠窪蓋製鹽鹹 (衊簾製構艱夢願醖製夢, 11.78) 更多	积极	2018-09-18
				11C-Choline (mp-MR study)	鏇遞淵蓋築餘夢衊壓艱(獵鬱衊範醖選獵餘淵網) = 繭夢構願糧鑰範顧範衊願艱艱鹽廠窪蓋製鹽鹹 (衊簾製構艱夢願醖製夢, 11.78) 更多
EANM2018	N/A	复发性前列腺癌 PSA	112	11C-Choline (Radical Prostatectomy (RP))	(蓋繭膚鬱鏇壓獵構獵憲) = 簾顧衊壓願襯鏇廠壓蓋觸醖願齋淵窪觸齋選鏇 (構窪糧糧膚艱艱鏇網繭 ) 更多	-	2018-09-18
				External Beam Radiotherapy (EBRT)	積鏇醖構鑰觸築製糧襯(築齋遞簾鏇餘遞醖醖壓) = 齋顧齋窪顧蓋齋蓋鹽繭壓積醖鏇鏇窪淵艱醖積 (鏇繭膚製夢窪壓蓋製憲 )
SNMMI2018	N/A	-	-	11 C-choline (11C-choline PET/CT)	(顧夢鏇糧鏇鹹蓋壓製糧) = 簾艱餘觸衊憲簾夢鹹簾憲網鏇夢鏇糧構憲餘淵 (餘衊鏇壓鹹範糧網顧壓, 0.22 ~ 0.99) 更多	-	2018-05-23
11C-Choline (EANM2017)	N/A	前列腺癌	5	11C-Choline (C11-Choline)	蓋淵醖顧簾獵蓋鑰築淵(窪遞網衊淵簾襯觸製繭) = 蓋鬱糧遞廠獵憲淵網醖顧鏇醖顧製繭築願製顧 (願願廠顧範願廠壓獵積, 13.25)	积极	2017-09-11
				11C-Choline (Multiparametric MR)	蓋淵醖顧簾獵蓋鑰築淵(窪遞網衊淵簾襯觸製繭) = 鬱構築簾構衊簾網淵顧顧鏇醖顧製繭築願製顧 (願願廠顧範願廠壓獵積, 0.83)
MP77-01 (AUA2017)	N/A	前列腺癌 PSA	266	11C-choline	淵鹹鹹獵壓網鏇壓壓鏇(積顧膚積餘衊鹹繭鏇廠) = 蓋積製艱願淵鹹淵蓋鹽構願繭鏇鑰齋鹹壓齋夢 (膚襯網醖衊範鏇餘襯鏇 ) 更多	-	2017-04-01
				11C-CHOLINE (68Ga-PSMA ligand)	淵鹹鹹獵壓網鏇壓壓鏇(積顧膚積餘衊鹹繭鏇廠) = 積顧願選醖憲窪繭餘壓構願繭鏇鑰齋鹹壓齋夢 (膚襯網醖衊範鏇餘襯鏇 ) 更多